TEMENOS
28.10.2020 09:32:06 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that it has appointed Joaquin De Valenzuela Muley as Senior Vice President and Business Line Director for Temenos Infinity. Joaquin will lead the global sales and business development of Temenos Infinity, the market-leading digital banking SaaS product. Joaquin will report directly to Jean-Michel Hilsenkopf, Chief Operating Officer at Temenos.
Temenos has seen strong demand for Temenos Infinity across challengers and incumbent banks. The company has recently invested over US$1 billion to acquire leading US-based SaaS companies Kony and Avoka to accelerate its digital banking capabilities. Temenos Infinity is the leading SaaS omnichannel digital banking product, covering customer engagement from acquisition and onboarding to origination and account servicing, through to long-term retention. More than 650 clients are using Temenos Infinity including HSBC and Regions.
Joaquin joins Temenos from Salesforce, where he led the Financial Services Industry business in EMEA and Latin America for the last five years. He also led the 2017 launch of Salesforce’s Financial Services Cloud in those regions. Prior to Salesforce, Joaquin held leadership positions at Oracle for 16 years within the Industry Financial Services Unit. During his 20+ years' experience, he has worked with retail and corporate banks and wealth management firms around the globe, including top financial institutions like BBVA, Bradesco, CaixaBank, Deutsche Bank, JP Morgan Chase, Standard Bank and UniCredit. He has supported banks as they move forward with their transformation initiatives in areas such as digital transformation, customer engagement, omnichannel, retail payments and core systems.
Joaquin De Valenzuela Muley, Business Line Director, Temenos Infinity, said : “It's not often in your career that you have the opportunity to join a company that is having such a transformative impact on a specific industry. Digital banking and SaaS are the future and I'm looking forward to being part of that alongside everyone at Temenos. I am excited about joining the Temenos family, that is a trusted advisor to banks and helping make them successful, transform their businesses, and put their customers at the center of everything they do.”
Max Chuard, Chief Executive Officer, Temenos, said: “I am delighted to welcome Joaquin to Temenos. We’re committed to expanding our sales leadership and support teams around the world to meet the needs of our growing customer base. We are seeing great customer demand for digital banking and SaaS and we expect this trend to continue. Joaquin is an inspirational and experienced business leader who will ensure we continue to build strong relationships with our customers and help us accelerate our growth in digital banking.”
Temenos Infinity helps banks succeed in the New Normal. It drives exceptional, personal customer experiences by combining digital technology with a human touch. With its advanced analytics, it drives customer acquisition and digital banking engagement, enabling financial institutions to increase digital revenues 5x and cut customer onboarding time by 75%. Financial institutions that use Temenos Infinity report a 20% higher Net Promoter Score. The SaaS product is recognized by top analyst firms Gartner, Forrester and Omdia as the leading digital engagement platform. Temenos recently won the IDC FinTech Rankings Real Results award with Temenos Infinity for its deployment at Atlantic Union Bank.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005498/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom